Fibrosis and hepatic steatosis
NON-INVASIVE DIAGNOSIS OF LIVER LESIONS BY BLOOD TESTS IN NAFLD
(P. Calès et al) (P.334)
All the main histological liver lesions (
fibrosis and steatosis) in
NAFLD can be correctly non-invasively quantified.
This abstract has been awarded as top 10% of posters during the EASL congress 2010.
See poster
FibroMeter’s performance
ACCURACY OF LIVER FIBROSIS CLASSIFICATIONS PROVIDED BY NON-INVASIVE TESTS
(P. Calès et al) (P.1048)
By using
classifications into fibrosis stages instead of a binary diagnostic (presence or not of significant fibrosis), the diagnostic accuracy of test classification is significantly better with FibroMeter compared to the other tests. This performance allows to the FibroMeter a
reliable diagnostic up to 80% in 100% of patients without liver biopsy.
See poster
ROBUSTNESS AND OPTIMIZATION OF AN ACCURATE BLOOD TEST FOR LIVER FIBROSIS
(P. Calès et al) (P.1049)
The diagnostic accuracy of a new
FibroMeter without
hyaluronate, nearly twice less expensive than the former version, is excellent regarding significant fibrosis and cirrhosis.
See poster
Co-infection
COMPARISON OF LIVER FIBROSIS BLOOD TESTS DEVELOPED FOR HCV WITH NEW SPECIFIC TESTS IN HIV/HCV CO-INFECTION
(P. Calès et al) (P.1047)
Non-invasive tests designed for hepatitis are less performant in HIV/HCV infections.
Specific FibroMeter for co-infection has shown higher performance than standard tests constructed for mono-infected patients;
this FibroMeter will be marketed in 2010.
See poster
Combination with Fibroscan
A NEW FIBROSIS STAGING METHOD PROVIDES VERY ACCURATE NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS WITHOUT LIVER BIOPSY
(J. Boursier et al) (P.1046)
The non-invasive diagnosis of liver fibrosis in patients with hepatitis C is improved by
a combination of FibroMeter with Fibroscan. A new combining fibrosis stage classification provides a diagnosis
in 100% of patients with 88% accuracy without any liver biopsy.
See poster
